Interview with Jean-Pierre Delwart, Chief Executive Officer, Eurogentec Belgium
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Address: Rue du Bois Saint Jean, 5, 4102 Seraing,Belgium
Tel: +32 4 372 74 00
Web: http://www.eurogentec.com/eu-home.html
Eurogentec S.A., part of Kaneka Corporation, is a leading global supplier of innovative reagents, kits, specialty products and custom services. Through its three inter-related business units (BU), the company provides high quality products to scientists involved in the life science, biotechnology, diagnostic and pharmaceutical markets. Eurogentec is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market.
The Life Science Research BU is specialized in innovative solutions in Genomics and Proteomics. Expert in small and large-scale synthesis, Eurogentec proposes a wide range of reagents, kits and consumables for Life Science applications such as Custom Oligonucleotides, high performance PCR/qPCR Kits & Reagents (including high pure Diamond Taq® DNA Polymerases), catalogue dyes, peptides & antibodies. Eurogentec is also specialist in the design and synthesis of custom peptides and production of custom antibodies (including a 28-day Speedy protocol) as well as producing pre-dispensed assays in a GMP environment.
The In Vitro Diagnostics BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases for use in Molecular Diagnostic applications. As a certified ISO 13485 and GMP compliant manufacturer, our manufacturing processes take place in classified clean rooms with controlled processes and full traceability. Our production facilities in Belgium and US enable high quality materials for the in vitro Diagnostic community.
The GMP BioManufacturing BU is a full-service Contract Manufacturing Organization (CMO) and offers significant know-how in process development, technology transfer, formulation, scale-up and manufacturing of GMP proteins, protein conjugates, plasmids and bacterial vaccines for pre-clinical, clinical and commercial uses, all according to FDA and EMA requirements. Experts in microbial production (E. coli, P. pastoris, etc), Eurogentec offers various development strategies based on protein refolding, periplasmic expression, and protein expression by secretion. As a one-stop shop, Eurogentec provides a complete gene to injectable service offering.
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains…
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
During the COVID-19 pandemic and the multi-stakeholder collaboration needed to find solutions, AstraZeneca launched the Partnership for Health System Sustainability and Resilience (PHSSR) in collaboration with KPMG, the London School…
Erik Present outlines Healixia’s progress in the past three years as the association which brings together medical professionals from across the Belgian healthcare and life sciences ecosystem has grown. Present…
PharmaScan BeLux is a non-profit organization established by pharma.be and Medaxes with the objective to collect and share reliable data on medicines delivered by pharmaceutical companies and distributors to healthcare…
Eli Lilly Belgium’s Frederic Clais discusses the potential impact of upcoming reform of the country’s access and reimbursement system, the country’s enduring relevance to the company as home to its…
Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million…
One year into his first country management assignment at Takeda Belgium, Michael Nesrallah reflects on his initial impressions of the Belgian pharma market as well as its similarities and differences…
Alexander Natz of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) casts his eye over the potential effects of the upcoming EU Pharmaceutical Legislation for small- and medium-sized enterprises in Europe.…
After a 25-year-long career at Roche, spent at local affiliates in Switzerland, Germany, and the Netherlands, as well as in global positions in Switzerland and the US, Marie-José Borst took…
With over 140 operating biotech companies representing almost a quarter of Europe’s biotech market and a strong network of universities and research institutes, Belgium boasts a solid biotech ecosystem that…
Belgium’s drug reimbursement system has become increasingly lengthy and complex, compromising patient access to innovative medicines. The roadmap recently presented by the Minister of Health and the Belgian National Institute…
See our Cookie Privacy Policy Here
